Sarah Cannon Research Institute (SCRI), an oncology research organization conducting community-based clinical trials, and Bristol Myers Squibb, a global biopharmaceutical company, have announced an expanded strategic collaboration aimed at accelerating the development of innovative cancer therapies and increasing access to clinical trials for patients across the U.S. Central to the collaboration is SCRI’s Accelero, a next-generation clinical trial delivery model that streamlines operations an...